This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

4SC-203

4SC AG

Drug Names(s): 4SC-203

Description: 4SC-203 is a novel, small molecule, multi-targetkinase inhibitor which has a unique selectivityprofile against FLT3, FLT3 mutants and VEGF-receptors. FLT3 is involved in the growth and maturation of normal blood cells, while VEGF receptor tyrosine kinases are involved in angiogenesis.

4SC-203 News

Scrip Asia Deal Watch: Antibody-Drug Conjugates Reign With Alliances Involving Celltrion, Miracogen & WuXi Biologics

Pink Sheet Keeping Track: Approvals For Mayzent, Mavenclad, Duaklir, Jatenzo And Cimzia

Scrip Pipeline Watch: Phase III Readouts For Vibegron, Doria And Ameluz

Pink Sheet Keeping Track: Two Goal Date Extensions, Another Herceptin Biosimilar Approval, And A BLA Withdrawal

Additional information available to subscribers only:

Targets
Routes
Catalysts
Designations
Events

Request a Free Demo Subscriber Login Search for another drug